A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Summary

This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent intranasal FluMist vaccine. Three hundred healthy adults will receive a single dose of vaccine or placebo and will be followed for 180 days after study vaccination.

Timeline

Start

2012-05

Primary completion

2012-11

Completion

2012-11

Drugs

Indications